



July 15, 2025

The Honorable Gary Peters
U.S. Senate
724 Hart Senate Office Building
Washington, DC 20510

The Honorable Jeff Van Drew, DMD
U.S. House of Representatives
466 Cannon House Office Building
Washington, DC 20515

The Honorable Marsha Blackburn
U.S. Senate
357 Dirksen Senate Office Building
Washington, DC 20510

The Honorable Angie Craig
U.S. House of Representatives
1110 Longworth House Office Building
Washington, DC 20515

The Honorable Ted Budd
U.S. Senate
354 Russell Senate Office Building
Washington, DC 20510

Dear Senators Peters, Blackburn and Budd and Representatives Van Drew and Craig:

On behalf of the American Association of Oral and Maxillofacial Surgeons (AAOMS), the professional association that represents more than 9,000 oral and maxillofacial surgeons (OMSs) in the United States, I wish to thank you for your committed leadership to preventing drug shortages by reintroducing the RAPID Reserve Act (S 2062/HR 3955).

As the surgical branch of dentistry – and the bridge to medicine – oral and maxillofacial surgeons (OMSs) provide vital services that are urgent, emergent and outpatient in nature.

OMSs are particularly prone to pharmaceutical and supply shortages due to their unique skillset and practice model. Most OMS offices function as small, independent operatories – providing office-based sedation and anesthesia on a daily basis to patients who would otherwise not tolerate treatment outside a hospital operating room.

Drug shortages continue to be an ongoing challenge despite past congressional efforts to address the issue. OMSs need access to – but have experienced shortages of – the following pharmacologics: emergency medications, anesthetics, analgesics, antibiotics, antiemetics and fluids.

When medications or supplies are unavailable – or available only at substantially elevated prices, as is typical during shortage periods – OMSs cannot offer their customary high level of care and access to treatment, which, in turn, significantly impacts the healthcare system.

Access to a stable and resilient supply chain is a crucial component to efforts to prevent future drug shortages. AAOMS believes the RAPID Reserve Act's focus on strengthening supply chain resiliency—by directing HHS to award contracts to U.S.-based manufacturers or those in designated foreign countries—will help achieve this goal by incentivizing manufacturers to maintain reserves of essential medications and build capacity to scale up production in response to future public health threats and supply chain disruptions.

AAOMS looks forward to working on advocating to advance the bill through the 119th Congress. On behalf of AAOMS, thank you again for your leadership on this important issue. For questions or additional information, please contact Jeanne Tuerk, director of government affairs at 800-822-6637, ext. 4321 or jtuerk@aaoms.org.

Sincerely,

A handwritten signature in black ink that reads "J. David Morrison" followed by a stylized flourish.

J. David Morrison, DMD
President